ClinicalTrials.gg
CompletedNCT00266123Updated Dec 27, 2007

Study Comparing Two Sirolimus Regimens vs. Tacrolimus and Mycophenolate Mofetil Regimen in Kidney Transplant Recipients

A Phase 4 interventional study of Sirolimus in Graft Rejection, Kidney Failure and Kidney Transplant, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2007-12-27.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing sirolimus in Renal Insufficiency — none open to participants now, none under way, none of them phase 3. Sirolimus · Renal Insufficiency.

Enrollment
Largest of 16
420 · median 63
Started
2004
with 1 other
Phase 4
6 of 16
none open now
Registered
9th of 16
by date
Lead sponsor
7 of 16
Wyeth is now a wholly owned subsidiary of Pfizer

Among the 16 studies testing sirolimus in Renal Insufficiency, this one has the largest enrollment, is one of 2 that started in 2004, is one of 6 in phase 4, and was the 9th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 16 studies testing sirolimus in Renal Insufficiency is open now. The open studies under Renal Insufficiency, anywhere →

About sirolimus

Sirolimus: first FDA approval 1999 (RAPAMUNE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing sirolimus in Renal Insufficiency as a file.
02

Study summary

To demonstrate the superiority of SRL + TAC elimination + corticosteroids (Group I) and SRL + MMF + corticosteroids (Group II) to TAC + MMF + corticosteroids (Group III) with respect to renal allograft function at month 12 post-transplantation.

03

Conditions studied

  • Graft Rejection
  • Kidney Failure
  • Kidney Transplant

Browse trials for

Keywords

  • Kidney Failure
  • Kidney Transplant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age > 18 years.
  • End-stage renal disease with subjects scheduled to receive a primary or secondary renal allograft from a cadaveric donor, from a living-unrelated mismatched donor, or from a living-related mismatched donor. Unreported HLA values will be considered a match.
  • Women of must have a negative serum pregnancy test before administration of assigned treatment and agree to use a medically acceptable method of throughout the treatment period and for 3 months following discontinuation of assigned treatment.

Other inclusions apply.

Exclusion criteria

Exclusion Criteria:

  • Evidence of active systemic or localized major infection.
  • Known to SRL or its derivatives, macrolide antibiotics, , TAC or MMF.
  • Multiple organ transplants (i.e., prior or concurrent transplantation of any organs other than renal transplant).

Other exclusions apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
420 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Kidney function at 52 weeks after transplantation.

Secondary outcomes

  1. Kidney function at 26, 78 and 104 weeks after transplantation

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2004 and a completion of Jul 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2005
First posted
Dec 15, 2005
Start
Mar 2004
CompletionActual
Jul 2007
Last update
Dec 27, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00266123
First posted
Dec 15, 2005
Start date
Mar 2004
Completion
Jul 2007
Last update
Dec 27, 2007

Study contacts

Medical Monitor
study director · Wyeth Reseach
Trial Manager
principal investigator · For Belgium, trials-BEL@wyeth.com
Trial Manager
principal investigator · For France, infomedfrance@wyeth.com
Trial Manager
principal investigator · For Germany, MedinfoDEU@wyeth.com
Trial Manager
principal investigator · For Italy, decresg@wyeth.com
Trial Manager
principal investigator · For Poland, WPWZMED@wyeth.com
Trial Manager
principal investigator · For Spain, infomed@wyeth.com
Trial Manager
principal investigator · For Switzerland, med@wyeth.com
Trial Manager
principal investigator · For United Kingdom, ukmedinfo@wyeth.com
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion